{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:44:43Z","timestamp":1793227483890,"version":"4.5.0"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Davis | Pfizer Pharmaceuticals"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,10,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Ceftazidime-avibactam (CZA) and ceftolozane-tazobactam (C\/T) are important agents for treating multidrug-resistant\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      infections. In this study, we evaluated the molecular characteristics of 300 globally collected clinical\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      isolates non-susceptible (NS) to CZA, C\/T, or both agents. Isolates were CZA-NS and C\/T-NS (\n                      <jats:italic>n<\/jats:italic>\n                      = 57), CZA-susceptible (S) and C\/T-NS (\n                      <jats:italic>n<\/jats:italic>\n                      = 145), or CZA-NS and C\/T-S (\n                      <jats:italic>n<\/jats:italic>\n                      = 98) selected from the Antimicrobial Testing Leadership and Surveillance (ATLAS) surveillance program from 2020 to 2021. Characterization was by whole-genome sequencing. Analysis was performed to identify \u03b2-lactamase genes and mutations that impact efflux regulation, AmpC regulation, and target binding (PBP3). Of the 57 CZA-NS+C\/T-NS isolates, 64.9% carried a metallo-\u03b2-lactamase (MBL), and a cumulative 84.2% carried any non-intrinsic \u03b2-lactamase [i.e., not\n                      <jats:italic>Pseudomonas-<\/jats:italic>\n                      derived cephalosporinase (PDC) or OXA-50-like]. Of the 145 CZA-S+C\/T-NS isolates, 26.2% carried an extended-spectrum \u03b2-lactamase (ESBL) and no carbapenemase, 17.9% carried a serine-carbapenemase, and 42.1% were negative for non-intrinsic \u03b2-lactamases. Of 98 CZA-NS+C\/T-S isolates, 34.7% carried mutations previously described as causing an upregulation of the MexAB-OprM efflux pump, while only 9.2% carried a non-intrinsic \u03b2-lactamase, and no resistance mechanism was identified in 29.6% of these isolates. MBLs were present in most isolates NS to both agents. More than half of the CZA-S+C\/T-NS isolates carried serine \u03b2-lactamases. The most frequently identified resistance mechanism identified in CZA-NS+C\/T-S isolates was a marker indicating the upregulation of MexAB-OprM. No mechanism was identified that is thought to support resistance to these agents in numerous isolates. This may be due in part to the fact that whole genome sequencing (WGS) cannot directly measure gene expression of chromosomal resistance mechanisms.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00670-24","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T09:01:19Z","timestamp":1725958879000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Molecular characterization of clinically isolated\n                    <i>Pseudomonas aeruginosa<\/i>\n                    with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021"],"prefix":"10.1128","volume":"68","author":[{"given":"H.","family":"Li","sequence":"first","affiliation":[{"name":"IHMA, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9327-1894","authenticated-orcid":true,"given":"A.","family":"Oliver","sequence":"additional","affiliation":[{"name":"Microbiology Service, Son Espases University Hospital, IdISBa, CIBERINFEC, Palma, Illes Balears, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-5665","authenticated-orcid":true,"given":"R. K.","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Pfizer, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Stone","sequence":"additional","affiliation":[{"name":"Pfizer, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3941-6589","authenticated-orcid":false,"given":"M.","family":"Estabrook","sequence":"additional","affiliation":[{"name":"IHMA, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01635-6"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10091126"},{"key":"e_1_3_4_4_2","first-page":"825","article-title":"Ceftolozane\/tazobactam: a new option in the treatment of complicated Gram-negative infections","volume":"39","author":"Sorbera M","year":"2014","unstructured":"Sorbera M, Chung E, Ho CW, Marzella N. 2014. Ceftolozane\/tazobactam: a new option in the treatment of complicated Gram-negative infections. P T 39:825\u2013832.","journal-title":"P T"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00897-16"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00524-19"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01291-13"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01342-06"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056858"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02012-13"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02445-17"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02622-15"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03113-15"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02318-20"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/2049-632X.12208"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01388-12"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.01997-14"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02462-13"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01183-17"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00825-15"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx424"},{"key":"e_1_3_4_22_2","volume-title":"CLSI standard M07","author":"Clinical and Laboratory Standards Institute","year":"2024","unstructured":"Clinical and Laboratory Standards Institute. 2024 Susceptibility tests for bacteria that grow aerobically. In CLSI standard M07, 11th ed. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, USA, 19087-1898.","edition":"11"},{"key":"e_1_3_4_23_2","volume-title":"CLSI supplement M100","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2023","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2023. Performance standards for antimicrobial susceptibility testing. In CLSI supplement M100, 33rd ed. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, USA 19087-1898.","edition":"33"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa345"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.14826.1"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad080"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1633-1641.2006"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1013092107"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01589-17"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00704-06"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00257-10"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00035-09"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2199"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.12.6969-6977.2004"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02538-18"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05621-5"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2002.02855.x"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz305"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab301"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz243"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3322-3327.2000"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00408"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01117-20"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx136"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00670-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00670-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T11:46:02Z","timestamp":1728387962000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00670-24"}},"subtitle":[],"editor":[{"given":"Boudewijn L.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,8]]}},"alternative-id":["10.1128\/aac.00670-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00670-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"2024-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00670-24"}}